TIVA, along with recent advances in it
Reading File
Finding Sources
Searching PubMed
"total intravenous anesthesia" AND advances
Searching the Web
TIVA total intravenous anesthesia recent advances 2024 2025
Reading File
Finding Sources
Reading Article
Reading Article
Reading Web Page
TIVA total intravenous anesthesia advances target controlled infusion
Reading File
Finding Sources
Searching PubMed
"total intravenous anesthesia" AND remimazolam OR ciprofol
Reading File
Finding Sources
Reading Article
I now have comprehensive material from textbooks and recent literature. Let me compose the full answer.
Total Intravenous Anesthesia (TIVA)
Definition and Concept
TIVA is a technique for inducing and maintaining general anesthesia exclusively via intravenous agents - with no volatile inhalational agents used at any point. It achieves the classic triad of anesthesia (unconsciousness, analgesia, and muscle relaxation) entirely through IV drugs, either by intermittent bolus, manually controlled infusion, or target-controlled infusion (TCI).
- Morgan & Mikhail's Clinical Anesthesiology 7e, p. 842
- Miller's Anesthesia 10e, p. 3103
Pharmacological Backbone
Propofol - The Cornerstone
Propofol (2,6-diisopropylphenol) remains the most widely used hypnotic agent in TIVA. Key properties:
- Rapid onset (~30 sec), short context-sensitive half-life
- Antiemetic properties - reduces PONV significantly
- Rapid, clear-headed emergence
- Dose: Induction 1-2.5 mg/kg IV; Maintenance 25-100 mcg/kg/min infusion
- Cardiac surgery TIVA: propofol 0.5-1.5 mg/kg induction, then 25-100 mcg/kg/min maintenance
- TCI target concentration: typically 1.5-2 mcg/mL for cardiac surgery; 3-6 mcg/mL for general surgery
Remifentanil - The Ideal TIVA Opioid
Ultra-short-acting synthetic opioid, metabolized by nonspecific plasma and tissue esterases (not liver-dependent).
- Context-sensitive half-life remains ~3-4 min regardless of infusion duration
- Reduces propofol requirements by up to 50%
- Dose: 0-1 mcg/kg bolus + 0.25-1 mcg/kg/min infusion
- Key limitation: No residual analgesia after cessation - must plan postoperative pain management before stopping
- The propofol + remifentanil TCI combination is the most common worldwide TIVA regimen
Other Agents
- Ketamine (sub-anesthetic doses): preserves airway reflexes and hemodynamic stability; useful as adjunct in high-risk patients
- Dexmedetomidine: alpha-2 agonist adjunct; reduces volatile/IV anesthetic requirements, opioid-sparing, and attenuates hemodynamic stress response
- Midazolam/benzodiazepines: often used for premedication or co-induction; reduce propofol requirements
- Neuromuscular blockers: added when needed; do not form part of the hypnotic-analgesic core
Delivery Methods
1. Manual Rate Infusion (Conventional Pumps)
- Fixed-rate or stepwise manually adjusted infusions
- Based on integrated PK-PD models (Table-based dosing)
- Less precise than TCI; requires careful titration
- Still valid when TCI pumps are unavailable
2. Target-Controlled Infusion (TCI)
The key technology that made TIVA practical and precise.
- Computer-driven syringe pump with embedded pharmacokinetic models
- Clinician sets a desired target blood or effect-site concentration (Cp or Ce); the pump continuously recalculates infusion rates
- For propofol: input age + weight; desired blood concentration (mcg/mL)
- Diprifusor (AstraZeneca): first commercial TCI device; widely available outside the USA; uses Marsh PK model
- Schnider model: effect-site targeting; considers lean body mass; more widely validated
Hardware requirements for safe TIVA (Association of Anaesthetists / SIVA 2019 Guidelines):
- Luer-lock connectors at both ends of infusion sets
- Anti-siphon valve on the drug delivery line
- Anti-reflux valve on fluid administration line
- Drug and fluid lines should join as close to the patient as possible (minimize dead space)
- IV cannula should remain visible throughout anesthesia
- Processed EEG (pEEG) monitoring recommended when neuromuscular blocking drugs are used
Miller's Anesthesia 10e, p. 3101-3104
Depth of Anesthesia Monitoring
A key safety requirement with TIVA - unlike volatile agents, there is no expired gas concentration to guide dosing.
- Processed EEG (pEEG) - e.g., BIS (Bispectral Index), Entropy (M-Entropy/SE), NeuroSENSE
- BIS target for general anesthesia: 40-60
- Reduces risk of intraoperative awareness - which is higher with TIVA than with volatile agents
- Guidelines recommend pEEG monitoring any time TIVA is combined with neuromuscular blockers
- NSRI (Noxious Stimulus Response Index): newer combined PK-PD display showing probability of unconsciousness and non-response to intubation
- Medvis / SmartPilot displays: real-time visualization of drug effect-site concentrations, synergistic interactions, and 10-min forward predictions
Miller's Anesthesia 10e, pp. 3100-3104
Advantages of TIVA
| Advantage | Mechanism / Evidence |
|---|---|
| Reduced PONV | Propofol has direct antiemetic properties |
| Lower intraoperative awareness risk when monitored | Precise drug titration with TCI + pEEG |
| Faster, clearer-headed emergence | Short-acting agents with low context-sensitive half-lives |
| No airway pollution | No volatile agents; no scavenging required |
| Reduced environmental footprint | Significantly lower greenhouse gas emissions vs inhalational anesthesia |
| Better for TIVA in remote/unusual locations | No anesthesia workstation with vaporizers needed |
| Advantageous for neurophysiologic monitoring (SSEP/MEP) | Less interference with cortical evoked potentials |
| Cardiac surgery "fast-track" | Earlier extubation, shorter ICU stay, earlier discharge |
| COVID-19 era advantage | No aerosolization from volatile agents; confirmed utility during the pandemic |
Disadvantages and Risks
- Intraoperative awareness - higher risk than volatile agents if pEEG not used, or if IV access fails silently
- IV access failure (TIVAAC) - a critical hazard; drug infused into extravasated site or disconnected line without alarm; standard monitoring (SpO2, etc.) may not immediately detect
- Propofol Infusion Syndrome (PRIS) - rare but life-threatening; lactic acidosis, rhabdomyolysis, cardiac arrhythmias, renal failure; risk increases with high doses (>5 mg/kg/hr) over prolonged periods (>48 h), especially in critically ill/pediatric patients
- Pain on injection (propofol) - mitigated by lidocaine pretreatment or use of large vein, lipid microemulsion formulations
- Remifentanil-induced hyperalgesia - can paradoxically increase postoperative pain sensitivity if used in high doses
- No residual analgesia when remifentanil-based TIVA ends - plan ahead
Special Populations
Cardiac Surgery
Propofol-remifentanil TIVA has largely replaced pure high-dose opioid techniques in cardiac surgery. Benefits include faster extubation (1-6 h) vs. overnight ventilation with high-dose fentanyl. TCI propofol target 1.5-2 mcg/mL during bypass; remifentanil 0.25-1 mcg/kg/min.
- Morgan & Mikhail 7e, p. 843
Pediatric TIVA
Children have age-dependent differences in volume of distribution, protein binding, and clearance. Specific validated pediatric TCI models:
- Paedfusor model: from age 1 year / weight ≥5 kg
- Kataria model: from age 3 years / weight ≥15 kg
- Rigby-Jones, Davis, Minto models also exist
- General principle: younger children need proportionally higher maintenance doses than adults due to larger volume of distribution
- Neonates: conservative, carefully titrated dosing due to immature pharmacokinetics
Recent Advances in TIVA (2023-2026)
1. Remimazolam
A new benzodiazepine analogue designed as a TIVA-friendly agent.
- Metabolized by tissue esterases (similar to remifentanil) - organ-independent clearance
- Context-sensitive half-life ~7 min; fully reversible with flumazenil
- Hemodynamically stable - less hypotension than propofol
- No injection pain
- FDA-approved for procedural sedation and general anesthesia induction in adults
- Pediatric evidence still limited (as of 2026 review by Quintão et al., PMID 41817234)
2. Ciprofol (HSK3486)
A structural analogue of propofol with a cyclopropyl substitution.
- Significantly less injection pain (RR 0.15 vs. propofol; p < 0.0001) - the major advantage
- Less hypotension during induction (RR 0.82 vs. propofol; p = 0.03)
- Non-inferior to propofol for anesthesia success
- Currently approved and increasingly used in China; under investigation elsewhere
- Meta-analysis (Akhtar et al. 2024, PMID 38412619): 13 RCTs, 1998 patients - ciprofol equally effective, better tolerated
- Network meta-analysis (Zhou et al. 2025, PMID 40340730) confirmed superior safety vs propofol for endoscopy
3. EEG-Guided and Combined PK-EEG Strategies
- EEG-based titration is now recommended for all TIVA cases involving neuromuscular blockade (2019 guidelines, reinforced in 2026 pediatric review)
- Combined pharmacokinetic + EEG strategies improve safety particularly in infants where pharmacokinetic variability is highest
- Universal TCI models (valid across all age groups) are being developed to standardize dosing
4. TIVA and Cancer Outcomes
Multiple retrospective studies and several RCTs have examined whether TIVA vs. volatile anesthesia affects cancer recurrence, metastasis, or survival.
- Proposed mechanism: volatile agents suppress NK cell function and may upregulate HIF-1α; propofol may be immunoprotective
- Current conclusion (2025 review, Owolabi & Tsai, PMID 40084514; 2026 review Ge et al. PMID 41987795): No definitive proof that anesthetic technique changes long-term cancer outcomes - awaiting results of large RCTs (e.g., TOPMED trial)
5. TIVA in Obesity
A 2025 systematic review and meta-analysis (Domene et al., J Anesth Analg Crit Care 2025) compared TIVA vs. inhalational anesthesia in obese patients (13 RCTs). TIVA was associated with lower PONV and faster emergence; multimodal analgesia adjuncts are recommended.
6. Environmental Sustainability
A growing evidence base confirms that TIVA produces substantially lower greenhouse gas emissions than desflurane, sevoflurane, or isoflurane - contributing to global efforts to "green" anesthesia. This is now a recognized reason to prefer TIVA in institutional sustainability frameworks.
- Quintão et al. 2026 (PMID 41817234) explicitly highlights this as a driver of increasing global TIVA adoption.
7. TIVA in PONV and ERAS
- Propofol-based TIVA is a Level A recommendation in many ERAS (Enhanced Recovery After Surgery) protocols for high-PONV-risk patients
- 2026 narrative review (Dombrower et al., PMID 42194789) reinforces propofol infusion as a PONV-prevention strategy within ERAS pathways
8. Advanced Infusion Technology
- Modern syringe pumps now include automated syringe size recognition, drug libraries with dosing alerts, weight-based dosing calculators, and integration with pEEG monitors
- Pharmacodynamic display systems (SmartPilot View, Medvis) show real-time synergy between propofol and opioids, with forward 10-min predictions of anesthetic depth - a major step toward "closed-loop" TIVA
- True closed-loop TIVA (automated feedback from BIS/EEG to pump rate) remains an active research area but is not yet in routine clinical use
Summary Table
| Domain | Key Point |
|---|---|
| Primary agents | Propofol + remifentanil (TCI, most common globally) |
| TCI models | Marsh/Diprifusor; Schnider; Paedfusor/Kataria (pediatric) |
| Safety monitoring | pEEG (BIS/Entropy) mandatory with NMBDs |
| New hypnotics | Remimazolam (organ-independent metabolism, reversible); Ciprofol (less pain, less hypotension) |
| Pediatric | Age-specific PK models; EEG-guided dosing in infants; remimazolam under study |
| Cancer | No proven outcome benefit of TIVA vs volatile; trials ongoing |
| Sustainability | Much lower GHG emissions than volatile agents |
| ERAS/PONV | Level A recommendation for high-risk patients |
| Major risk | Awareness (use pEEG), IV access failure, PRIS (rare) |
Key references:
- Morgan & Mikhail's Clinical Anesthesiology 7e, pp. 842-843
- Miller's Anesthesia 10e, pp. 3100-3105
- Quintão VC et al. "Update on TIVA in children." Curr Opin Anaesthesiol 2026 [PMID 41817234]
- Akhtar SMM et al. "Ciprofol vs. Propofol - systematic review." J Clin Anesth 2024 [PMID 38412619]
- Zhou S et al. "Remimazolam, ciprofol, and propofol in endoscopy - network meta-analysis." BMC Anaesthesiol 2025 [PMID 40340730]
- Owolabi A & Tsai E. "Anesthetic considerations in cancer care." Curr Opin Anaesthesiol 2025 [PMID 40084514]
- Nimmo et al. "Guidelines for safe practice of TIVA." Anaesthesia 2019;74:139-141
This is a shared conversation. Sign in to Orris to start your own chat.